Holen Sie sich die Stockscreener-App
4.525
0.34%
-0.075
Schlusskurs vom Vortag:
$4.45
Offen:
$4.35
24-Stunden-Volumen:
23,488
Relative Volume:
0.03
Marktkapitalisierung:
$117.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-1.5976
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
+24.23%
1M Leistung:
+89.94%
6M Leistung:
-45.91%
1J Leistung:
-66.43%
1-Tages-Spanne:
$4.28
$4.525
1-Wochen-Bereich:
$3.36
$5.55
52-Wochen-Spanne:
$1.45
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.525 | 117.85M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.30 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.57 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
650.61 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.20 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
255.25 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (NASDAQ:LXEO) - Seeking Alpha
Lexeo Therapeutics to Present New CMC Data at the 28th - GlobeNewswire
Lexeo Therapeutics Inc Inc. (LXEO) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - The Manila Times
Was anything positive for Lexeo Therapeutics Inc (LXEO) stock last session? - uspostnews.com
Lexeo Therapeutics to Present Data on AAV Manufacturing at ASGCT Annual Meeting - Nasdaq
Insider Selling: Townsend Richard Nolan, Lexeo Therapeutics Inc [LXEO] Chief Executive Officer divested 4,326 shares - knoxdaily.com
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Thursday - Defense World
Analyzing Ocugen (NASDAQ:OCGN) and Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX
Geode Capital Management LLC Has $3.74 Million Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of “Buy” from Brokerages - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025 - CGTLive®
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Bought by Wellington Management Group LLP - Defense World
Chardan Capital Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $22.00 - MarketBeat
Chardan Capital Has Positive Outlook of LXEO FY2025 Earnings - Defense World
Alzheimer's Disease Drug Development Pipeline: 2025-A Surge - openPR.com
Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
Lexeo’s Gene Therapy LX2006 Reduces Abnormal LVMI in Patients With Friedreich Ataxia Cardiomyopathy - CGTLive®
Gene Therapy Shows Promise for Fatal Heart Condition Tied to Friedreich Ataxia - Managed Healthcare Executive
Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc. - TipRanks
Chardan Research Adjusts Lexeo Therapeutics Price Target to $22 From $25, Maintains Buy Rating - marketscreener.com
Lexeo’s Cardiac Gene Therapy Achieves Good Early Trial Results - Inside Precision Medicine
Lexeo Plots Pivotal Path for Friedreich’s Ataxia Gene Therapy After ‘Compelling’ Phase I/II Data - BioSpace
H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock - Investing.com
H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock By Investing.com - Investing.com UK
Lexeo Therapeutics price target lowered to $22 from $25 at Chardan - TipRanks
Lexeo touts Friedreich ataxia cardiomyopathy candidate as 'best-in-class' - FirstWord Pharma
Lexeo Therapeutics Reports Positive Interim Trial Results - TipRanks
Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers - Endpoints News
Lexeo Therapeutics Says Potential FA Cardiomyopathy Therapy Improves Cardiac Biomarkers - marketscreener.com
Lexeo Therapeutics announces ‘positive’ Interim Phase 1/2 data for LX2006 - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study - MarketScreener
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewswire
Breakthrough Data: Gene Therapy Shows 25% Heart Improvement in Fatal Rare Disease - Stock Titan
Lexeo stock hits 52-week low at $2.31 amid sharp annual decline - Investing.com Canada
Lexeo stock hits 52-week low at $2.31 amid sharp annual decline By Investing.com - Investing.com South Africa
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks - BioPharma Dive
Q1 EPS Estimate for Lexeo Therapeutics Raised by Analyst - The AM Reporter
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Raised by Bank of New York Mellon Corp - Defense World
What is Chardan Capital’s Estimate for LXEO FY2025 Earnings? - Defense World
Q1 EPS Estimate for Lexeo Therapeutics Increased by Analyst - Defense World
HC Wainwright Reaffirms Buy Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
What is Leerink Partnrs’ Forecast for LXEO FY2025 Earnings? - Defense World
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw? - MSN
Analysts Offer Predictions for LXEO Q1 Earnings - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $20.00 at Royal Bank of Canada - Defense World
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
H.C. Wainwright maintains Buy on Lexeo stock, $23 target By Investing.com - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| See Tai Sandi | Chief Development Officer |
Feb 19 '25 |
Sale |
4.41 |
1,486 |
6,558 |
53,889 |
| Adler Eric | Chief Medical Officer |
Feb 19 '25 |
Sale |
4.41 |
2,359 |
10,410 |
68,266 |
| Robertson Jenny | Chief Legal Officer |
Feb 19 '25 |
Sale |
4.41 |
2,101 |
9,272 |
57,899 |
1.72%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):